Pneumonia

Vaxcyte to Present at the Jefferies Virtual Healthcare Conference

Retrieved on: 
Thursday, May 27, 2021
Medical specialties, Pneumonia, Pneumococcal conjugate vaccine, Clinical medicine, Health care, Vaccine, Conjugate vaccine, Vaccines, Pneumococcal vaccine, Vaccination schedule

A live webcast of the presentation can be accessed through the Investors & Media section of the Companys website at http://investors.vaxcyte.com .

Key Points: 
  • A live webcast of the presentation can be accessed through the Investors & Media section of the Companys website at http://investors.vaxcyte.com .
  • A replay of the webcast will be available for approximately 30 days following the conference.
  • Vaxcyte is a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide.
  • Vaxcytes lead vaccine candidate, VAX-24, is a preclinical, 24-valent broad-spectrum pneumococcal conjugate vaccine (PCV) being developed for the prevention of invasive pneumococcal disease (IPD).

Sinovant Sciences and Nabriva Therapeutics Announce Positive Topline Results from Phase 3 Trial of Lefamulin in Chinese Adults with Community Acquired Bacterial Pneumonia (CABP)

Retrieved on: 
Tuesday, May 25, 2021
Chemical compounds, Drugs, Cyclopropanes, Moxifloxacin, Health care, Antibiotic, Pneumonia, Empiric

Subjects were randomized 2:1 to lefamulin and moxifloxacin and stratified by prior antibiotic exposure, pneumonia severity index (PSI) risk class, and renal impairment.

Key Points: 
  • Subjects were randomized 2:1 to lefamulin and moxifloxacin and stratified by prior antibiotic exposure, pneumonia severity index (PSI) risk class, and renal impairment.
  • These results are similar to those observed in the global Phase 3 LEAP 1 and LEAP 2 clinical trials conducted by Nabriva.
  • We are delighted with the results of this trial, said Dr. Rae Yuan, CEO of Sinovant.
  • These data strongly support the use of lefamulin as an empiric monotherapy for CABP, a disease that affects millions of Chinese patients annually.

Citius Pharmaceuticals Selected to Receive Best Poster Award at the International Society for Cell and Gene Therapy 2021 Annual Meeting

Retrieved on: 
Tuesday, May 25, 2021
Medical specialties, Respiratory diseases, Clinical medicine, Intensive care medicine, Acute respiratory distress syndrome, Respiratory physiology, Pulmonary edema, Mechanical ventilation, Shortness of breath, Pneumonia, Chest pain, Diffuse alveolar damage

ARDS accounts for approximately 10% of all ICU admissions and almost 25% of patients requiring mechanical ventilation.

Key Points: 
  • ARDS accounts for approximately 10% of all ICU admissions and almost 25% of patients requiring mechanical ventilation.
  • Survivors of ARDS are often left with severe long-term illness and disability.
  • ARDS is sometimes initially diagnosed as pneumonia or pulmonary edema (fluid in the lungs from heart disease).
  • Symptoms of ARDS include shortness of breath, rapid breathing and heart rate, chest pain (particularly while inhaling), and bluish skin coloration.

Pfizer Initiates Study Exploring Coadministration of Its 20-valent Pneumococcal Conjugate Vaccine Candidate Along With a Third Dose of the Pfizer-BioNTech COVID-19 Vaccine in Older Adults

Retrieved on: 
Monday, May 24, 2021
Infectious diseases, Biotechnology, Pharmaceutical, Health, Health sciences, Health, Pneumococcal conjugate vaccine, Pneumonia, BioNTech, Medical research, Vaccines, Vaccination, CRM197, Pfizer, Vaccine, BioNTech, Pfizer-BioNTech COVID-19 Vaccine, 20vPnC Adult, Pfizer: Breakthroughs That Change Patients’ Lives, PFIZER-BIONTECH COVID-19 VACCINE, 20VPNC ADULT, PFIZER: BREAKTHROUGHS THAT CHANGE PATIENTS’ LIVES

There are no data available on the interchangeability of the Pfizer-BioNTech COVID-19 Vaccine with other COVID-19 vaccines to complete the vaccination series.

Key Points: 
  • There are no data available on the interchangeability of the Pfizer-BioNTech COVID-19 Vaccine with other COVID-19 vaccines to complete the vaccination series.
  • Also, in February 2021, Pfizer announced that the European Medicines Agency (EMA) accepted for review the Marketing Authorization Application (MAA) for 20vPnC for adults ages 18 years and older.
  • Pfizers 20vPnC vaccine candidate includes capsular polysaccharide conjugates for the 13 serotypes in Prevnar 13 (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]).
  • Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance.

Merck Announces Positive Topline Results from PNEU-DIRECTION (V114-027) and PNEU-PLAN (V114-024) Phase 3 Pediatric Studies for V114, Merck’s Investigational 15-valent Pneumococcal Conjugate Vaccine

Retrieved on: 
Thursday, May 20, 2021
Health, Infectious diseases, Clinical trials, General Health, Pharmaceutical, Biotechnology, Pneumonia, Medical specialties, Clinical medicine, Microbiology, Pneumococcal conjugate vaccine, Pneumococcal infection, Vaccine, Pneumococcal vaccine, Streptococcus pneumoniae, Conjugate vaccine, PNEU-DIRECTION, PNEU-PLAN, V114, Pneumococcal Disease, Merck, PNEU-DIRECTION, PNEU-PLAN, V114, PNEUMOCOCCAL DISEASE, MERCK

\xe2\x80\x9cAt Merck, our goal is to expand coverage to new serotypes not targeted by currently available pediatric pneumococcal conjugate vaccines, while maintaining a strong immune response to current vaccine serotypes so as to help sustain progress achieved to date.

Key Points: 
  • \xe2\x80\x9cAt Merck, our goal is to expand coverage to new serotypes not targeted by currently available pediatric pneumococcal conjugate vaccines, while maintaining a strong immune response to current vaccine serotypes so as to help sustain progress achieved to date.
  • Children under the age of 2 are particularly vulnerable to pneumococcal infection and invasive pneumococcal disease incidence remains highest in the first year of life.
  • Serotypes 22F, 33F and 3 represent a sizeable portion of invasive pneumococcal disease cases in adults and children.
  • This supports the need for robust immune suppression of current vaccine serotypes while also expanding serotype coverage.

Daiichi Sankyo Advances Science Across Three Lead DXd ADCs with New Data in Multiple Cancers at 2021 ASCO Virtual Meeting

Retrieved on: 
Wednesday, May 19, 2021
Research, Clinical trials, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Oncology, Pneumonitis, Shortness of breath, Pneumonia

Monitor for and promptly investigate signs and symptoms including cough, dyspnea, fever, and other new or worsening respiratory symptoms.

Key Points: 
  • Monitor for and promptly investigate signs and symptoms including cough, dyspnea, fever, and other new or worsening respiratory symptoms.
  • Advise patients of the risk and to immediately report symptoms.\nExposure to ENHERTU during pregnancy can cause embryo-fetal harm.
  • For asymptomatic ILD/pneumonitis (Grade 1), interrupt ENHERTU until resolved to Grade 0, then if resolved in \xe2\x89\xa428 days from date of onset, maintain dose.
  • No overall differences in efficacy were observed between patients \xe2\x89\xa565 years of age compared to younger patients.

Avisa Diagnostics Begins Trading on the Canadian Securities Exchange

Retrieved on: 
Tuesday, May 18, 2021
Respiratory diseases, Medical specialties, Clinical medicine, Respiratory therapy, Infectious diseases, Pneumonia, Ventilator-associated pneumonia, Bronchiectasis, Ventilator, Sputum, Respiratory tract infection, COVID-19

The ABT measures bacterial load in suspected respiratory infections and may represent an effective alternative to sputum culture-based diagnostics.

Key Points: 
  • The ABT measures bacterial load in suspected respiratory infections and may represent an effective alternative to sputum culture-based diagnostics.
  • Approximately 25% of the 1.7 million intensive care unit (ICU) patients who are on ventilators each year develop VAP.
  • The non-radioactive, isotopic ratio of 13CO2/12CO2 in the exhaled breath of the patient is measured by the Avisa spectrometer.
  • Avisa is planning pivotal trials in Post-COVID-19 bronchiectasis and ventilator-associated pneumonia and plans to submit Investigational Device Exemption applications to the U.S. FDA for these trials next year.

Veracyte Announces Data Reinforcing the Diagnostic Performance and Utility of the Envisia Genomic Classifier in ILD Diagnosis

Retrieved on: 
Friday, May 14, 2021
Health, Hospitals, Managed care, Clinical trials, Pharmaceutical, Biotechnology, Lung disorders, Pneumonia, Interstitial lung disease, Usual interstitial pneumonia, Classifier, Statistical classification, UIP

(Nasdaq: VCYT) announced that data reinforcing the diagnostic performance and utility of the Envisia\xc2\xae Genomic Classifier are being shared at the American Thoracic Society (ATS) 2021 International Conference, taking place today through May 18.

Key Points: 
  • (Nasdaq: VCYT) announced that data reinforcing the diagnostic performance and utility of the Envisia\xc2\xae Genomic Classifier are being shared at the American Thoracic Society (ATS) 2021 International Conference, taking place today through May 18.
  • The Envisia Genomic Classifier detects a genomic pattern of usual interstitial pneumonia (UIP) to improve ILD diagnostic and prognostic confidence.
  • Researchers retrospectively analyzed 144 samples from ILD patients enrolled in two prior, independent clinical validation cohorts.
  • \xe2\x80\x9cWe are excited to execute on this plan, beginning with the Envisia classifier.\xe2\x80\x9d\nMultiple abstracts relating to the Envisia Genomic Classifier can be viewed at the links below.

Vaxcyte Reports First Quarter 2021 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, May 11, 2021
Medical specialties, Pneumonia, Vaccination, Pneumococcal conjugate vaccine, Clinical medicine, Health care, PCV, Vaccine, Conjugate vaccine, Vaccines, Pneumococcal vaccine

Mrs. Graesser brings to Vaxcyte over 20 years of healthcare communications experience and expertise across a variety of areas, including corporate communications and strategy, public relations and organizational communications.

Key Points: 
  • Mrs. Graesser brings to Vaxcyte over 20 years of healthcare communications experience and expertise across a variety of areas, including corporate communications and strategy, public relations and organizational communications.
  • Vaxcyte\xe2\x80\x99s lead vaccine candidate, VAX-24, is a preclinical, 24-valent broad-spectrum pneumococcal conjugate vaccine (PCV) being developed for the prevention of invasive pneumococcal disease.
  • Vaxcyte undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in its expectations.
  • Readers should not rely upon the information in this press release as current or accurate after its publication date.\n'

Vaxcyte Announces Publication of Preclinical Data Supporting the Potential of VAX-24 for the Prevention of Invasive Pneumococcal Disease

Retrieved on: 
Monday, May 10, 2021
Pneumonia, Medical specialties, Microbiology, Clinical medicine, Pneumococcal conjugate vaccine, PCV, Streptococcus pneumoniae, Vaccine, Conjugate vaccine, Pneumococcal vaccine

\xe2\x80\x9cThese preclinical data add to the growing body of evidence supporting the potential for VAX-24, using Vaxcyte\xe2\x80\x99s proprietary cell-free protein synthesis platform, to become the broadest-spectrum PCV.

Key Points: 
  • \xe2\x80\x9cThese preclinical data add to the growing body of evidence supporting the potential for VAX-24, using Vaxcyte\xe2\x80\x99s proprietary cell-free protein synthesis platform, to become the broadest-spectrum PCV.
  • Antibiotics are used to treat pneumococcal disease, but some strains of the bacteria have developed resistance to treatments.
  • Vaxcyte\xe2\x80\x99s lead vaccine candidate, VAX-24, is a preclinical, 24-valent broad-spectrum pneumococcal conjugate vaccine (PCV) being developed for the prevention of invasive pneumococcal disease.
  • Readers should not rely upon the information in this press release as current or accurate after its publication date.\n'